EyePoint Pharmaceuticals (EYPT) TD Cowen 46th Annual Health Care Conference summary

Recent clinical progress and trial updates

• Dosed patients in both phase III diabetic macular edema (DME) trials, COMO and CAPRI, in Q1 as planned.

• DME trials are international, enrolling about 240 patients each, leveraging safety data from wet AMD trials to keep sample size low.

• Both DME trials expected to be fully enrolled by Q3 this year, with top-line data anticipated in Q4 2027.

• Wet AMD trials (LUGANO and LUCIA) are fully enrolled, with low dropout rates and positive masked safety data so far.

• Top-line results from LUGANO expected around August, with LUCIA about eight weeks behind.

Mechanistic insights and differentiation

• New mechanistic finding: DURAVYU is a potent JAK1 blocker, leading to significant IL-6 pathway inhibition.

• IL-6 blockade is believed to be a key differentiator, especially in DME, as it addresses inflammation and may improve outcomes.

• DURAVYU is the only sustained-release, repeatable anti-VEGF, anti-IL-6, and anti-PGF therapy in development for these indications.

Phase II learnings and phase III expectations

• Phase II data showed DURAVYU was statistically non-inferior to EYLEA in efficacy, with a strong safety profile and no significant adverse events.

• Improved supplement criteria and inclusion of more treatment-naive patients in phase III are expected to reduce unnecessary supplemental injections.

• Phase III aims to demonstrate non-inferiority, safety, and superiority in reducing treatment burden, with a potential 40–60% reduction in injections.